US2008124321A1PendingUtilityA1

ISOLATED BOVINE IgG HEAVY CHAIN PROTEIN AND ITS USE AS AN ANTIMICROBIAL

Assignee: LAURIDSEN GROUP INCPriority: Jan 30, 2001Filed: Oct 29, 2007Published: May 29, 2008
Est. expiryJan 30, 2021(expired)· nominal 20-yr term from priority
C07K 2317/10C07K 16/00A61P 31/12A61P 31/04A61K 2039/505A61P 43/00C07K 16/065
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A new protein derived from acid hydrolyzed IgG concentrate which has a molecular weight of about 55,000, and is activated by heat within the defined narrow temperature range provides resulting product that has a protective mechanism for bacterial and viral invasion of living cells.

Claims

exact text as granted — not AI-modified
1 . A treated and isolated IgG fraction, comprising:
 acid hydrolyzed IgG fraction which has been heated for from 15 minutes to 1 hour at a temperature of from 35° C. to 40° C., and thereafter neutralized.   
     
     
         2 . The treated and isolated IgG fraction of  claim 1  which has been hydrolyzed with from 0.1N to 0.2N acid. 
     
     
         3 . The treated and isolated IgG fraction of  claim 2  wherein the acid is selected from the group consisting of hydrochloric acid, phosphoric acid and sulfuric acid. 
     
     
         4 . The treated and isolated IgG fraction of  claim 1  which has a molecular weight of about 55,000. 
     
     
         5 . The treated and isolated IgG fraction of  claim 1  wherein the IgG traction is derived from the sources selected from the group consisting of bovine or porcine blood or colostrum, egg or whey. 
     
     
         6 . The treated and isolated IgG fraction of  claim 5  wherein the IgG is derived from bovine blood. 
     
     
         7 . The treated and isolated concentrate of  claim 1  which is spray dried. 
     
     
         8 . A method of providing bacterial static and viral static activity, comprising:
 oral dosing of a mammalian species with an anti-bacterial and antiviral effective amount of a treated and isolated IgG fraction which is acid hydrolyzed, and has been heated from 15 minutes to 1.0 hour at a temperature of 35° C. to 40° C., and thereafter neutralized.   
     
     
         9 . The method of  claim 8  wherein the amount dosed is sufficient to provide a dosage of 0.25 mg/ml in the mammal's gut. 
     
     
         10 . The method of  claim 8  wherein the dose is up to 5 grams/day.

Join the waitlist — get patent alerts

Track US2008124321A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.